Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (DCT) receiving palliative chemotherapy in the United States

Next Previous
Trial Profile

Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (DCT) receiving palliative chemotherapy in the United States

Status: Planning
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 211 (Primary)
  • Indications Germ cell cancer; Penile cancer; Prostate cancer; Testicular cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 Aug 2024 According to a BioNTech media release, the analysis of this study will inform the design of the Company's planned pivotal clinical trial to evaluate BNT211 in patients with germ cell tumors.
  • 05 Aug 2024 According to a BioNTech media release, data from this trial presented at the 2024 ASCO Annual Meeting.
  • 22 May 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top